Check-CapSTU:7CC -0.96%30 Return-on-Tangible-Equity is -65.69% as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Check-Cap ranks better than 86.53% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Check-Cap's annualized net income for the quarter that ended in Dec. 2025 was €-1.83 Mil. Check-Cap's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €2.79 Mil. Therefore, Check-Cap's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -65.69%.
The historical rank and industry rank for Check-Cap's Return-on-Tangible-Equity or its related term are showing as below:
STU:7CC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -226.19 Med: -94.22 Max: 656.62
Current: 247.21
During the past 13 years, Check-Cap's highest Return-on-Tangible-Equity was 656.62%. The lowest was -226.19%. And the median was -94.22%.
STU:7CC's Return-on-Tangible-Equity is ranked better than 86.53% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs STU:7CC: 247.21
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Check-Cap Return-on-Tangible-Equity Related Terms
Check-Cap Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Check-Cap's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7CC vs ADVB, XWEL, NDRA: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Check-Cap's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Check-Cap's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -65.69% mean?
Check-Cap (STU:7CC) has a Return-on-Tangible-Equity of -65.69% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #26 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 13.5%.
Is Check-Cap's Return-on-Tangible-Equity too high?
Check-Cap's current Return-on-Tangible-Equity is -65.69%. Based on the distribution chart, Check-Cap ranks #26 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Check-Cap has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's Return-on-Tangible-Equity compare to ADVB and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #26 out of 193 companies for Return-on-Tangible-Equity. This places Check-Cap in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Check-Cap and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current Return-on-Tangible-Equity is -65.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current Return-on-Tangible-Equity of -65.69%. The current Return-on-Tangible-Equity is -65.69%. Check-Cap's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current Return-on-Tangible-Equity is -65.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
30GF Score
Get the complete analysis for STU:7CC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CC has been successfully added to your 
